PT-141
PT-141 (Bremelanotide) is a melanocortin receptor agonist that acts centrally to enhance sexual desire and arousal. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. In compounding, it is prescribed for both male and female sexual dysfunction.
At a Glance
Category
Sexual Health
Demand
High
Route
Subcutaneous injection, intranasal
FDA Status
FDA-approved as Vyleesi for HSDD; compounded versions available for broader off-label use
Also Known As
How PT-141 Works
PT-141 is a cyclic heptapeptide that activates melanocortin-4 receptors (MC4R) in the medial preoptic area and paraventricular nucleus of the hypothalamus, triggering downstream dopaminergic and oxytocinergic pathways involved in sexual arousal [3]. Unlike PDE5 inhibitors that act peripherally on vascular smooth muscle, PT-141 modulates central nervous system circuits governing desire and motivation [2]. It also demonstrates partial agonist activity at MC3R, contributing to its effects on both arousal and appetite regulation [4].
Clinical Evidence
The RECONNECT Phase III trials (two pivotal studies, n=1247) demonstrated statistically significant increases in satisfying sexual events and desire scores versus placebo in premenopausal women with HSDD, leading to FDA approval as Vyleesi in June 2019 [1][2]. Phase II studies in men with erectile dysfunction showed improved erection quality in approximately 70% of subjects, including those unresponsive to sildenafil [4]. Clinical pharmacology data confirm peak onset at 45 to 60 minutes post-injection with duration of action of 12 to 24 hours [3]. The melanocortin mechanism represents the first centrally acting pharmacotherapy approved specifically for female sexual desire [1].
Clinical Uses
Patient Selection and Screening
FDA-approved for premenopausal women with acquired, generalized HSDD not explained by relationship, medical, or psychiatric factors [1][2]. Off-label candidates include men with erectile dysfunction refractory to PDE5 inhibitors (particularly those with desire-based dysfunction) [4], postmenopausal women with HSDD, and patients on SSRI/SNRI medications with treatment-emergent sexual dysfunction [3]. Contraindicated in patients with uncontrolled hypertension or cardiovascular disease. Screen for concurrent naltrexone use, which may reduce efficacy.
Dosing and Administration
FDA-approved dose (Vyleesi) is 1.75 mg subcutaneous, administered at least 45 minutes before anticipated sexual activity [1]. Maximum frequency is one dose per 24 hours and no more than 8 doses per month [2]. For patients experiencing significant nausea, initiating at 1.0 mg and titrating to 1.75 mg over 2 to 3 uses improves tolerability. Compounded formulations for male patients are typically dosed at 1.5 to 2.0 mg subcutaneous [4]. Intranasal formulations (historical) were dosed at 10 to 20 mg but are no longer preferred due to variable absorption and higher nausea rates [3].
Route: Subcutaneous injection, intranasal
Protocol notes: Administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity. FDA-approved dose is 1.75mg as needed, not to exceed one dose per 24 hours or 8 doses per month.
Safety and Monitoring
Potential Side Effects
- ● Nausea (40% incidence; most common and potentially dose-limiting)
- ● Flushing and facial warmth (25% incidence)
- ● Headache (mild to moderate, typically resolves within hours)
- ● Transient blood pressure elevation (average 6-8 mmHg systolic)
- ● Injection site reactions (erythema, pruritus)
Clinical Considerations
- ● FDA-approved (Vyleesi) for HSDD in premenopausal women
- ● Common side effects include nausea, flushing, and headache; nausea may be dose-limiting
- ● Can cause transient blood pressure elevation; screen for uncontrolled hypertension
- ● Not recommended for use with naltrexone (may reduce efficacy)
- ● Limit to 8 doses per month per FDA labeling
Practice Economics
Sexual health is a high-demand, cash-pay category with strong patient willingness to pay out-of-pocket. PT-141's FDA-approved status (Vyleesi) provides regulatory credibility and reduces liability concerns compared to unapproved peptides [1]. Practices can offer full sexual wellness programs combining PT-141 with hormone optimization, generating recurring revenue from an underserved and growing patient demographic [2].
FDA Category Status
FDA-approved as Vyleesi for HSDD; compounded versions available for broader off-label use
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify current status before prescribing.
Pharmacy Integrations
Prescribe PT-141 through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
How does PT-141 differ from PDE5 inhibitors like sildenafil? expand_more
Can PT-141 be prescribed for men? expand_more
What is the nausea management strategy for PT-141? expand_more
References
- FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. FDA News Release, June 21, 2019.
- Kingsberg SA et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908.
- Diamond LE et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-38.
- Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. J Sex Med. 2008;5(5):1088-96.
Related Peptides in Sexual Health
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable regulations. Always verify FDA category status and compounding eligibility before prescribing.
Launch a Peptide Program With Karpa
Karpa handles intake, licensed prescribing, and direct-to-patient pharmacy fulfillment across all 50 states. No medical license required.
Book a Demo